All data are based on the daily closing price as of May 8, 2026
s

Shin Nippon Biomedical Laboratories

2395.TSE
9.16 USD
0.28
+3.15%

Overview

Last close
9.16 usd
Market cap
381.39M usd
52 week high
12.51 usd
52 week low
8.03 usd
Target price
17.52 usd

Valuation

P/E
12.4139
Forward P/E
N/A
Price/Sales
1.8418
Price/Book Value
1.1105
Enterprise Value
541.47M usd
EV/Revenue
2.4462
EV/EBITDA
9.5831

Key financials

Revenue TTM
200.30M usd
Gross Profit TTM
88.27M usd
EBITDA TTM
33.76M usd
Earnings per Share
0.71 usd
Dividend
0.32 usd
Total assets
722.05M usd
Net debt
166.76M usd

About

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation delivery technology, discovery of future seeds, and business promotion activities; and development of artificial seed production for Japanese eels. In addition, it operates hotels accommodations facilities under the Villa Amafuru Oka and HOTEL Freesia names; and develops and operates geothermal and hot spring thermal power plants. Shin Nippon Biomedical Laboratories, Ltd. was founded in 1957 and is headquartered in Kagoshima, Japan.
  • Symbol
    2395.TSE
  • Exchange
    TSE
  • Isin
    JP3379950003
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Diagnostics & Research
  • CEO
    Dr. Ryoichi Nagata F.F.P.M., M.D., Ph.D.
  • Headquarter
    Kagoshima
  • Web site
    https://www.snbl.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top